Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects. Background: Serdemetan is a compound that can cause replicative stress ...
Final report of phase I clinical, pharmacokinetic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors. A phase I dose-escalation ...
One PK/PD model helps researchers predict the disposition of a drug from the body and its penetration to the target organs. The model incorporates data from animal tests on the new drug and on a ...
Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development. Y-mAbs Therapeutics, Inc. announced the presentation of preclinical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results